-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients...
Single healthcare-focused institutional investor $5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in full...
MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular...
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet...
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company...
Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - May...
Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington's diseaseOne of Evotec's largest strategic drug...
Toronto, Ontario--(Newsfile Corp. - May 27, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light...
GOTHENBURG, SE / ACCESSWIRE / May 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 27, 2024 - IRLAB Therapeutics...
Dublin, Ireland--(Newsfile Corp. - May 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that its...
TORONTO, ON / ACCESSWIRE / May 24, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
CHICAGO, IL / ACCESSWIRE / May 24, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 studyIRVINE, Calif., May 24,...
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T...
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic...
WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing...
WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today...
- BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer,...
- Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients...